Aptose Biosciences Inc. financial data

Symbol
APTO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
66 Wellington Street West, Suite 5300, Td Bank Tower Box 48, Toronto, Ontario, Canada
State of incorporation
Ontario, Canada
Fiscal year end
December 31
Former names
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) (to 11/26/2014), LORUS THERAPEUTICS INC (to 9/2/2014), IMUTEC PHARMA INC (to 3/24/1998)
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 107 % -41.3%
Debt-to-equity -385 % -412%
Return On Equity 647 %
Return On Assets -227 % -10.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.55M shares -83.8%
Common Stock, Shares, Outstanding 2.01M shares +658%
Entity Public Float 22.1M USD -25.4%
Common Stock, Value, Issued 457M USD +2.83%
Weighted Average Number of Shares Outstanding, Basic 699K shares +210%
Weighted Average Number of Shares Outstanding, Diluted 699K shares +210%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.1M USD -54.6%
General and Administrative Expense 11.2M USD -28.5%
Nonoperating Income (Expense) 827K USD -28%
Net Income (Loss) Attributable to Parent -25.4M USD +50.3%
Earnings Per Share, Basic -36.4 USD/shares -365%
Earnings Per Share, Diluted -36.4 USD/shares -365%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.15M USD -33.5%
Cash, Cash Equivalents, and Short-term Investments 6.7M USD -28%
Other Assets, Current 570K USD -5%
Assets, Current 9.53M USD -19.9%
Property, Plant and Equipment, Net 26K USD -82.9%
Operating Lease, Right-of-Use Asset 571K USD -39.4%
Assets 10.1M USD -22%
Accounts Payable, Current 1.26M USD -64%
Employee-related Liabilities, Current 982K USD -50.6%
Accrued Liabilities, Current 2.77M USD -68.6%
Liabilities, Current 4.46M USD -70.8%
Operating Lease, Liability, Noncurrent 193K USD -68.9%
Liabilities 14.7M USD -7.68%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.32M USD 0%
Retained Earnings (Accumulated Deficit) -541M USD -4.93%
Stockholders' Equity Attributable to Parent -4.54M USD -56.6%
Liabilities and Equity 10.1M USD -22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -36M USD +19.3%
Net Cash Provided by (Used in) Financing Activities 33.4M USD +384%
Net Cash Provided by (Used in) Investing Activities 18K USD -99.8%
Common Stock, Shares, Issued 2.01M shares +658%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.55M USD +90.8%
Deferred Tax Assets, Valuation Allowance 98M USD +7.38%
Deferred Tax Assets, Gross 98M USD +7.38%
Operating Lease, Liability 621K USD -38.8%
Payments to Acquire Property, Plant, and Equipment 29K USD +20.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.4M USD +50.3%
Lessee, Operating Lease, Liability, to be Paid 659K USD -41.1%
Property, Plant and Equipment, Gross 544K USD -32.1%
Operating Lease, Liability, Current 428K USD +8.63%
Lessee, Operating Lease, Liability, to be Paid, Year Two 197K USD -57.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 462K USD +0.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +13.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 38K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 198K USD
Deferred Tax Assets, Operating Loss Carryforwards 80M USD +8.7%
Operating Lease, Payments 458K USD +13.1%
Additional Paid in Capital 83.3M USD +15.5%
Depreciation, Depletion and Amortization 46K USD -53.1%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.06M USD -71%